2023/24 年度加拿大艾伯塔省使用常规数据估算早期流感疫苗有效性。
Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season.
机构信息
Public Health Analytics, Alberta Health, Edmonton, Alberta.
These authors contributed equally to this work and share first authorship.
出版信息
Euro Surveill. 2024 Jan;29(2). doi: 10.2807/1560-7917.ES.2024.29.2.2300709.
Timely and precise influenza vaccine effectiveness (VE) estimates are needed to guide public health messaging and impact vaccine uptake immediately. Using routinely collected laboratory, vaccination and health administrative data from Alberta, Canada, we estimated influenza VE against infection for the 2023/24 season on a near real-time basis, to late December, at 61% (95% CI: 58-64) against influenza A(H1N1), 49% (95% CI: 28-63) against influenza A(H3N2) and 75% (95% CI: 58-85) against influenza B.
需要及时、准确的流感疫苗有效性 (VE) 估计值，以指导公共卫生信息传递，并立即影响疫苗接种率。我们使用来自加拿大阿尔伯塔省的常规收集的实验室、疫苗接种和卫生管理数据，在接近实时的基础上，对 2023/24 季节的流感进行了估计，截至 12 月底，对甲型流感 (H1N1) 的有效性为 61%（95%CI：58-64），对甲型流感 (H3N2) 的有效性为 49%（95%CI：28-63），对乙型流感的有效性为 75%（95%CI：58-85）。
Zotero 插件